Efficacy of selpercatinib as a first-line treatment for RET-fusion positive non-small-cell lung cancer: a novel two-stage Bayesian network meta-analysis.

The two-stage approach to incorporate single-arm trial data within NMAs is readily applicable within health technology assessment. Enabling the earlier assessment of single-arm trials, via pseudo comparator arms, will provide payers with greater confidence in anticipated treatment effects. In light of the joint clinical assessment, incorporation of single-arm trials within NMA facilitates the reporting of predicted treatment effects relative to multiple relevant comparators, which is important when considering the use of interventions for the global market.